KR20110019977A - Pharmaceutical composition for the prevention and treatment of stress and panic disorder - Google Patents
Pharmaceutical composition for the prevention and treatment of stress and panic disorder Download PDFInfo
- Publication number
- KR20110019977A KR20110019977A KR1020090077620A KR20090077620A KR20110019977A KR 20110019977 A KR20110019977 A KR 20110019977A KR 1020090077620 A KR1020090077620 A KR 1020090077620A KR 20090077620 A KR20090077620 A KR 20090077620A KR 20110019977 A KR20110019977 A KR 20110019977A
- Authority
- KR
- South Korea
- Prior art keywords
- stress
- pharmaceutical composition
- prevention
- panic disorder
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000019906 panic disease Diseases 0.000 title claims abstract description 42
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 34
- 230000002265 prevention Effects 0.000 title claims abstract description 30
- 208000013200 Stress disease Diseases 0.000 title claims abstract description 27
- 239000000284 extract Substances 0.000 claims abstract description 22
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 17
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 17
- 210000003205 muscle Anatomy 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 12
- 230000036541 health Effects 0.000 claims description 11
- 235000013376 functional food Nutrition 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 244000309466 calf Species 0.000 claims description 2
- 238000004821 distillation Methods 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 13
- 206010022437 insomnia Diseases 0.000 abstract description 13
- 208000019901 Anxiety disease Diseases 0.000 abstract description 10
- 230000036506 anxiety Effects 0.000 abstract description 10
- 206010033557 Palpitations Diseases 0.000 abstract description 5
- 206010016256 fatigue Diseases 0.000 abstract description 5
- 208000020016 psychiatric disease Diseases 0.000 abstract description 4
- 206010003591 Ataxia Diseases 0.000 abstract description 3
- 230000002567 autonomic effect Effects 0.000 abstract description 3
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 17
- 239000000843 powder Substances 0.000 description 15
- 238000001467 acupuncture Methods 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 12
- 235000013372 meat Nutrition 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000003809 water extraction Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 3
- 206010029333 Neurosis Diseases 0.000 description 3
- 210000004100 adrenal gland Anatomy 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 208000015238 neurotic disease Diseases 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 206010033664 Panic attack Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 206010043269 Tension headache Diseases 0.000 description 2
- 208000008548 Tension-Type Headache Diseases 0.000 description 2
- 244000126014 Valeriana officinalis Species 0.000 description 2
- 235000013832 Valeriana officinalis Nutrition 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 235000016788 valerian Nutrition 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 241001342895 Chorus Species 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical group COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000792914 Valeriana Species 0.000 description 1
- 241001247821 Ziziphus Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000009045 body homeostasis Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- HAORKNGNJCEJBX-UHFFFAOYSA-N cyprodinil Chemical compound N=1C(C)=CC(C2CC2)=NC=1NC1=CC=CC=C1 HAORKNGNJCEJBX-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- -1 ethyl oleate Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 235000017468 valeriana Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/84—Valerianaceae (Valerian family), e.g. valerian
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/31—Foods, ingredients or supplements having a functional effect on health having an effect on comfort perception and well-being
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 스트레스 및 공황장애의 예방 및 치료용 약학적 조성물에 관한 것으로, 구체적으로는 힐초근 및 연자육을 포함하고, 상기 힐초근 및 연자육을 열수 추출한 추출물의 형태로 포함할 수 있다. The present invention relates to a pharmaceutical composition for the prevention and treatment of stress and panic disorder, and specifically includes heel herb root and lotus root, and may be in the form of an extract from the hydrothermal extract of the heel herb root and lotus root.
상기 스트레스 및 공황장애의 예방 및 치료용 약학적 조성물은 스트레스로 인한 불면증, 불안, 만성 피로등의 자율신경실조증 뿐만 아니라, 불안, 신경쇠약, 가슴 두근거림등의 공황장애의 예방 및 치료에 효과가 있을 뿐만 아니라 천연 유래의 물질을 포함하여 인체에 안전하고 장기간 사용하여도 부작용이 없다. The pharmaceutical composition for the prevention and treatment of stress and panic disorder is effective in the prevention and treatment of panic disorders such as anxiety, nervous breakdown, palpitations as well as autonomic ataxia due to insomnia, anxiety, chronic fatigue due to stress. Not only that, but also safe for the human body, including substances of natural origin, there are no side effects.
힐초근, 연자육, 스트레스, 불면증, 공황장애 Heel root, soft muscle, stress, insomnia, panic disorder
Description
본 발명은 스트레스 및 공황장애의 예방 및 치료용 약학적 조성물에 관한 것으로, 구체적으로는 스트레스로 인한 불면증, 불안, 만성 피로등의 자율신경실조증 뿐만 아니라, 불안, 신경쇠약, 가슴 두근거림등의 증상이 나타나는 공황장애의 예방 및 치료에 효과가 있는 약학적 조성물에 관한 것이다. The present invention relates to a pharmaceutical composition for the prevention and treatment of stress and panic disorder, specifically, symptoms such as anxiety, nervous breakdown, palpitation, as well as autonomic ataxia due to stress, insomnia, anxiety, chronic fatigue. The present invention relates to a pharmaceutical composition effective for preventing and treating panic disorder.
현대사회에서는 스트레스가 과도하게 발생하고 있기 때문에 스트레스는 사회적 문제가 된다. 일반적으로 생체에 미치는 자극이 일정한 정도 이상이 될 경우 생체는 그 자극의 종류에 관계없이 일정한 위협에 대한 반응으로 비특이적인 전신증후군(general adaptative syndrome)을 나타내는데 이를 스트레스라 정의한다. 이러한 반응은 신체에 다양한 현상으로 나타나는데 긴장성 두통, 편두통, 고혈압, 소화불량, 피로, 통증, 갱년기 장애, 발모, 피부 거칠어짐등을 일으키고, 만성적으로 지속되면 각종 신경증, 불면증, 위궤양등을 유발하기도 하고 신체의 생리활성, 면 역활성등이 저하되고 신체의 항상성이 깨짐으로써 신체의 저항성이 약화되어 다른 질병등이 유발되기 때문에 건강에 상당한 위협을 가하기도 하며 정신적 활동을 위축시키고 정서가 불안정해져 비정상적 활동을 유발하기도 한다. Stress is a social problem in modern society because stress is excessive. In general, when a stimulus affects a certain degree or more, the body shows a general adaptative syndrome, which is non-specific in response to a certain threat regardless of the type of stimulus, which is defined as stress. These reactions occur in various ways in the body, such as tension headaches, migraines, high blood pressure, indigestion, fatigue, pain, menopausal disorders, hair growth, skin roughness, and if chronically persisted, they cause various neurosis, insomnia, stomach ulcers, etc. As the body's physiological activity and immune activity are deteriorated and the body's homeostasis is broken, the body's resistance is weakened and other diseases are caused, which may pose a significant threat to health, reduce mental activity, and unstable emotions, resulting in abnormal activity. It may cause.
공황장애(panic disorder)는 특별한 이유 없이 예상치 못하게 나타나는 극단적인 불안 증상, 즉 공황발작(panic attack)이 주요한 특징인 질환이다. 공황발작은 극도의 공포심이 느껴지면서 심장이 터지도록 빨리 뛰거나 가슴이 답답하고 숨이 차며 땀이 나는 등 신체증상이 동반된 죽음에 이를 것 같은 극도의 불안 증상을 말한다. 최근의 연구는 심리사회적 요인과 더불어 생물학적 요인이 공황장애의 주요한 원인임을 밝히고 있다. 뇌 기능과 구조의 문제들이 보고 되고 있는데, 대표적인 것으로는 노르에피네프린(norepinephrine), 세로토닌(serotonin), 가바(GABA, -aminobutyric acid) 등 신경 전달물질 시스템의 이상, 측두엽, 전전두엽 등의 뇌 구조의 이상 등이다. 공황장애 환자의 경우 많은 수가 증상 발생 전 스트레스 상황을 경험하는 것으로 알려져 있다. Panic disorder is a condition characterized by extreme anxiety symptoms, panic attacks, which appear unexpectedly for no particular reason. Panic attacks are extreme symptoms of anxiety that can lead to death, accompanied by physical symptoms, such as a fast-paced heart bursting or feeling tight, breathing and sweating. Recent studies have shown that biological factors, along with psychosocial factors, are the leading cause of panic disorder. Problems with brain function and structure have been reported, such as abnormalities in neurotransmitter systems such as norepinephrine, serotonin, and GABA (GABA, -aminobutyric acid), and abnormal brain structures such as temporal lobe and frontal lobe. And so on. Many patients with panic disorder are known to experience stress before they develop symptoms.
한약제 또는 민간요법제로서 스트레스에 유용한 효과가 있다고 알려져 있는 인삼, 두충, 가시오가피등의 성분을 주성분으로 하는 각종 제재형태의 의약품들이 개발되어 다수 시판되고 있으나, 스트레스에 의해 유발되는 다양한 변화들중 일부 항목에만 효과가 있거나 약효가 미미한 것으로 나타나 있으며, 공황장애에 대한 한약제등의 연구는 미비한 실정이다. As a Chinese medicine or a folk remedy, various types of medicines have been developed and sold on the market, mainly containing ginseng, tofu, and thorny ginseng, which are known to have useful effects on stress. However, some of the various changes caused by stress Only effective or insignificant efficacy has been shown, and studies on panic disorders such as herbal medicines are inadequate.
상기의 문제점을 해결하고자, 본 발명의 목적은 스트레스로 인한 불면증, 불안, 만성 피로등의 자율신경실조증 뿐만 아니라, 불안, 신경쇠약, 가슴 두근거림등의 공황장애의 예방 및 치료에 효과가 있는 약학적 조성물을 제공하는 것이다. In order to solve the above problems, an object of the present invention is a pharmaceutical that is effective in the prevention and treatment of panic disorders such as anxiety, nervous breakdown, palpitations as well as autonomic ataxia due to insomnia, anxiety, chronic fatigue due to stress To provide a composition.
상기의 목적을 달성하고자 본 발명은,The present invention to achieve the above object,
힐초근 및 Hill Calves and
연자육을 포함하는 스트레스 및 공황장애의 예방 및 치료용 약학적 조성물을 제공한다. It provides a pharmaceutical composition for the prevention and treatment of stress and panic disorder, including soft muscle.
상기 힐초근은 조성물에 대하여 50 내지 95 중량부로 포함될 수 있다.The heel herb muscle may be included in an amount of 50 to 95 parts by weight based on the composition.
상기 연자육은 조성물에 대하여 5 내지 50 중량부로 포함될 수 있다. The soft meat may be included in an amount of 5 to 50 parts by weight based on the composition.
상기 약학적 조성물은 힐초근 및 연자육을 열수 추출하여 얻은 추출물일 수 있다. The pharmaceutical composition may be an extract obtained by hot water extraction of the heel chogeun and lotus root meat.
상기 약학적 조성물은 상기 조성물을 증류하여 얻은 약침액의 형태로 제형화될 수 있다. The pharmaceutical composition may be formulated in the form of a weak solution obtained by distilling the composition.
본 발명의 다른 목적을 달성하고자 본 발명은, The present invention to achieve another object of the present invention,
상기 약학적 조성물을 유효성분으로 포함하는 스트레스 및 공황장애 예방 및 개선용 건강기능식품을 제공한다. It provides a health functional food for preventing and improving stress and panic disorder comprising the pharmaceutical composition as an active ingredient.
본 발명의 약학적 조성물은 스트레스를 완화시켜 스트레스의 예방 및 치료에 우수한 약리효과를 나타낸다. 또한, 스트레스로 인하여 유발될 수 있는 긴장성 두통, 피로, 각종 신경증, 불면증등에도 효과를 나타낸다. The pharmaceutical composition of the present invention exhibits excellent pharmacological effects in the prevention and treatment of stress by relieving stress. In addition, it has an effect on tension headache, fatigue, various neurosis, insomnia, etc. that can be caused by stress.
본 발명의 약학적 조성물은 불안, 신경쇠약, 가슴 두근거림등의 공황장애의 예방 및 치료등에 우수한 약리효과를 나타낸다. The pharmaceutical composition of the present invention exhibits excellent pharmacological effects in the prevention and treatment of panic disorders such as anxiety, nervous breakdown and palpitations.
본 발명의 약학적 조성물은 천연 유래의 성분을 포함하여 인체에 안전하며 장기간 사용하여도 부작용이 없다. The pharmaceutical composition of the present invention is safe for the human body, including components derived from nature, and has no side effects even when used for a long time.
또한, 본 발명의 약학적 조성물은 스트레스 및 공항장애등의 예방 및 개선에 효과가 있는 건강기능식품등으로도 응용될 수 있다. In addition, the pharmaceutical composition of the present invention can be applied to health functional foods and the like that are effective in the prevention and improvement of stress and airport disorders.
이하, 당업자가 용이하게 실시할 수 있도록 상세히 설명한다. 본 발명은 다양하게 변형될 수 있고 여러 가지 형태를 취할 수 있으며, 여기서는 그에 따른 특별한 실시예에 대해서만 기술한다. 하지만 본 발명은 여기서 언급되는 특별한 형태 로 한정되는 것이 아닌 것으로 이해되어야 하며, 오히려 첨부된 청구범위에 의해 정의되는 본 발명의 정신과 범위 내에 있는 모든 변형물과 균등물 및 대체물을 포함하는 것으로 이해되어야 한다.It will be described below in detail to be easily carried out by those skilled in the art. The present invention may be variously modified and may take various forms, and only the specific embodiments thereof will be described here. It is to be understood, however, that the present invention is not limited to the specific forms referred to herein, but rather to include all modifications, equivalents and substitutions within the spirit and scope of the invention as defined by the appended claims. .
본 발명의 스트레스 및 공황장애의 예방 및 치료용 약학적 조성물은 힐초근( Valeriana faurie)을 포함한다. 상기 힐초근은 스트레스를 완화하고, 마음을 진정시켜 불면증 또는 각종 신경증등에 효과가 있다. The pharmaceutical composition for the prevention and treatment of stress and panic disorder of the present invention includes Valeriana faurie . The heel chogeuneun relieve stress, soothing the heart is effective in insomnia or various neurosis.
상기 힐초근은 쥐오줌풀의 뿌리를 말린 것을 말한다. 쥐오줌풀은 다소 습한 곳에서 자라고, 원줄기는 높이 40~90 cm이며 세로줄이 있고, 뿌리잎은 길이 50 cm 정도로 5 개의 작은잎은 깃꼴(羽狀)이며 긴 대가 있다. 줄기잎은 마주나고 홀수깃꼴겹잎(奇數羽狀複葉)으로 3~7개의 작은잎으로 구성되며 가장자리에 톱니가 있다. 꽃은 6~7월에 산방꽃차례[揀房花序]로 피고 연한 홍색이다. The heel herb refers to dried roots of Valerian. Valerian grows in a rather humid place, the main stem is 40 ~ 90 cm high, has a vertical line, and the root leaf is 50 cm long, 5 small leaves are feather-shaped and have long stems. Stem leaf is opposite, odd-shaped leaf leaf (奇數 羽狀 複葉) consists of 3 ~ 7 small leaves with serrated edge. Flowers bloom in June-July in inflorescences, light red.
본 발명의 조성물은 상기 힐초근을 파쇄한 뒤 분말화하여 포함하거나 상기 힐초근의 추출물을 포함할 수 있다. 상기 힐초근 추출물은 당업계에 공지된 통상적인 추출 방법으로 얻을 수 있다. 구체적으로는 유기용매 추출, 물을 이용한 수 추출 또는 초임계 추출로 얻을 수 있으며, 바람직하게는 인체에 대한 안전성을 고려하여 물을 이용한 수 추출로 얻을 수 있다. 상기 유기용매는 당업계에 공지된 것이 제한없이 사용될 수 있으며, 구체적으로는 메탄올, 에탄올, 이소프로필알코올, 부탄올 등의 저급 알코올; 글리세롤, 에틸렌글리콜, 프로필렌 글리콜, 1, 3-부틸렌 글리콜 등의 다가 알코올; 및 석유에테르, 메틸아세테이트, 에틸아세테이트, 벤젠, 헥산, 메틸렌클로라이드, 디에틸에테르, 디클로로메탄, 클로로포름등의 탄화수소계 용매로 이루어진 군으로부터 선택된 단독 또는 이들의 혼합물을 사용할 수 있으며, 상기 유기용매를 물과 혼합하여 추출용매로 사용할 수 있다. The composition of the present invention may be included after crushing the heel herb root and powdered or may include an extract of the heel herb muscle. The hilcho root extract can be obtained by conventional extraction methods known in the art. Specifically, it can be obtained by organic solvent extraction, water extraction using water or supercritical extraction, preferably by water extraction using water in consideration of safety to the human body. The organic solvent can be used without limitation those known in the art, specifically, lower alcohols such as methanol, ethanol, isopropyl alcohol, butanol; Polyhydric alcohols such as glycerol, ethylene glycol, propylene glycol and 1, 3-butylene glycol; And hydrocarbon solvents such as petroleum ether, methyl acetate, ethyl acetate, benzene, hexane, methylene chloride, diethyl ether, dichloromethane, and chloroform may be used alone or in a mixture thereof. It can be mixed with and used as an extraction solvent.
상기 힐초근은 조성물에 대하여 50 내지 95 중량부로 포함될 수 있다. 힐초근이 50 중량부 미만으로 포함되는 경우 스트레스로 인한 불면증등의 신경성 질환 또는 공항장애에 대한 예방 및 치료 효과가 미미할 수 있으며, 95 중량부를 초과하여 포함되는 경우 첨가량에 비해 효능의 상승정도가 적을 수 있어 비효율적이며, 건강기능식품등으로 제조시에 맛이나 풍미가 좋지 않을 수 있다. The heel herb muscle may be included in an amount of 50 to 95 parts by weight based on the composition. If less than 50 parts by weight of heel myo muscle may prevent the effect of preventing and treating neurological diseases such as insomnia due to stress or airport disorders, and when included in excess of 95 parts by weight, the increase in efficacy is less than the added amount It may be inefficient, and may not have good taste or flavor at the time of manufacturing as health food.
본 발명의 스트레스 및 공황장애의 예방 및 치료용 약학적 조성물은 연자육(蓮子肉)을 포함한다. 상기 연자육은 진정 및 신경안정의 효과가 있을뿐 아니라 힐초근과 병행하여 사용시 스트레스 및 공황장애의 예방 및 개선효과를 상승시키고, 혈기를 보충하는 역할을 하며 인체에 안전하고 식용으로 섭취하여도 무해하다.The pharmaceutical composition for the prevention and treatment of stress and panic disorder of the present invention includes a soft muscle (蓮 子 肉). In addition to the effects of sedation and neurostable, the lotus root is also effective in preventing and improving stress and panic disorder when used in combination with heel choso, and supplementing blood, and is safe for humans and ingestible for food. .
상기 연자육은 수련과의 연꽃(Nelumbo nucifera Gaertner)의 씨로서 종피를 벗겨 말린 약재를 말하며, 일본에서는 같은 식물을 연육(蓮肉)이라 부르고, 중국에서는 같은 식물의 씨앗을 연자(蓮子), 성숙한 씨앗 안의 건조된 어린잎과 어린뿌리를 연자심(蓮子心)이라 부른다. 연자육은 냄새가 거의 없으며 맛은 달아 한약이나 식품등에 포함시 거부감이 덜할 수 있다. 상기 연자육의 생김새는 타원형이나 공모양을 이루며 한쪽 끝이 둥글게 조금 두드러져 있다. 바깥면은 엷은 황갈색 또는 적갈색이고 회백색의 가루가 있고 가는 세로무늬와 비교적 확실한 맥상의 무늬가 있 다. 씨앗 껍질은 얇고 황갈색이며 벗기기 어렵다. 씨앗껍질 안에는 떡잎이 2개 있으며 황백색으로 두껍게되어 있고 가운데 빈틈에는 녹색의 연자심이 들어 있다. The lotus meat is the lotus of Nelumbo nucifera A seed of Gaertner ), which refers to a dried herb that has been peeled off of the seedling, and in Japan, the same plant is called yukyeon (,), and in China, the same plant seeds are soft-leaved, dried young leaves and young roots in mature seeds. It is called the heart (蓮 子 心). Yeonjagi has almost no smell and taste can be less rejected when included in Chinese medicine or food. The appearance of the lotus root is oval or ball-shaped, one end is rounded off slightly. The outer surface is pale yellowish brown or reddish brown with greyish white powder, thin vertical pattern and relatively clear vein pattern. Seed shells are thin, yellowish brown and hard to peel off. There are two cotyledons in the seed shell and it is thick white with yellowish white.
본 발명의 약학적 조성물은 상기 연자육을 파쇄하여 분말화하여 포함하거나 상기 연자육의 추출물을 포함할 수 있다. 상기 연자육 추출물은 유기용매 추출물, 물을 이용하여 추출한 수 추출물, 초임계 추출물등 당업계에 공지된 통상적인 추출 방법으로 얻어진 모든 추출물을 포함할 수 있으나, 인체의 안정성을 고려하여 물을 이용한 수 추출물이 바람직하다. 상기 유기용매는 상술하 바와 같다. The pharmaceutical composition of the present invention may be included by pulverizing and softening the soft magnetic meat or may include an extract of the soft magnetic meat. The lotus root extract may include any extract obtained by conventional extraction methods known in the art, such as organic solvent extract, water extract extracted using water, supercritical extract, water extract using water in consideration of the stability of the human body This is preferred. The organic solvent is as described above.
상기 연자육은 조성물에 대하여 5 내지 50 중량부로 포함될 수 있다. 상기 연자육이 5 중량부 미만으로 포함되는 경우 스트레스의 완화 및 공항장애등의 예방 및 치료효과가 미미하여 본 발명의 목적을 달성하기 어려울 수 있으며, 50 중량부를 초과하여 포함되는 경우 상대적으로 힐초근의 함량이 감소하여 스트레스의 완화 및 공항장애의 예방 및 치료효과가 감소할 수 있다. The soft meat may be included in an amount of 5 to 50 parts by weight based on the composition. When the soft lotus meat is included in less than 5 parts by weight, it may be difficult to achieve the object of the present invention because the effects of alleviation of stress and prevention and treatment of airport disorders are insignificant. This can reduce the effects of stress and reduce the prevention and treatment of airport disorders.
본 발명의 상기 힐초근 추출물 및 연자육 추출물은 상기한 추출용매뿐 아니라 다른 추출용매를 이용하여 실질적으로 동일한 효과를 나타내는 것이면 본 발명에 포함하며, 통상적인 정제과정을 거친 추출물도 포함한다. 구체적으로, 상기 힐초근 추출물 또는 연자육 추출물은 추출용매에 의한 추출물을 그대로 사용하거나 추출한 후 정제과정, 예를 들어 일정한 분자량으로 컷-오프값을 갖는 여과막을 이용한 막 분리, 크기, 전하, 소수성 또는 친화성에 따른 분리를 위한 다양한 크로마토그래피에 의한 분리등의 정제 과정을 추가적으로 실시하여 사용할 수 있다. The hilcho root extract and lotus root extract of the present invention is included in the present invention as long as it exhibits substantially the same effect using the above extraction solvent as well as other extraction solvents, and includes extracts that have undergone the usual purification process. Specifically, the heel chogeun extract or lotus root extract is used as it is or extract the extract by the extraction solvent after purification, for example, membrane separation, size, charge, hydrophobicity or affinity using a filter membrane having a cut-off value at a constant molecular weight Purification process such as separation by a variety of chromatography for separation according to sex can be additionally carried out.
본 발명의 스트레스 및 공황장애의 예방 및 치료용 약학적 조성물은 정제, 산제, 환제, 과립제, 캡슐제, 현탁액, 에멀전, 시럽, 에어로졸등의 경구형 제형으로 제조될 수 있다. 본 발명의 스트레스 및 공황장애의 예방 및 치료용 약학적 조성물의 경구 투여를 위한 고형제제는 약학적으로 허용되는 담체, 부형제, 충진제, 증량제, 결합제, 습윤제, 붕해제 또는 계면활성제등의 희석제를 추가로 포함할 수 있다. 상기 부형제로는 전분, 칼슘 카보네이트(calcium carbonate), 수크로오스(sucrose) 또는 락토오스(lactose), 젤라틴등을 사용할 수 있다. 구체적으로는, 힐초근 및 연자육의 분말에 부형제로 전분을 섞어 환제를 제조할 수 있다. Pharmaceutical compositions for the prevention and treatment of stress and panic disorder of the present invention can be prepared in oral dosage forms such as tablets, powders, pills, granules, capsules, suspensions, emulsions, syrups, aerosols. The solid preparation for oral administration of the pharmaceutical composition for the prevention and treatment of stress and panic disorder of the present invention is a diluent such as a pharmaceutically acceptable carrier, excipient, filler, extender, binder, wetting agent, disintegrant or surfactant. It can be included as. Starch, calcium carbonate (calcium carbonate), sucrose (sucrose) or lactose (lactose), gelatin and the like can be used as the excipient. Specifically, the pill may be prepared by mixing starch root with soft powder of starch as an excipient.
본 발명의 스트레스 및 공황장애의 예방 및 치료용 약학적 조성물은 멸균된 수용액, 액제, 비수성 용제, 현탁제, 유제, 동결건조 제제, 좌제, 주사제제등의 비경구 투여를 위한 제제로 제형화될 수 있다. 상기 비경구 투여를 위한 제제에는 프로필렌글리콜, 폴리에틸렌글리콜, 올리브오일등과 같은 식물성 오일, 에틸올레이트와 같은 주사 가능한 에스테르등이 포함될 수 있다. 상기 비경구 투여를 위한 제제는 공지의 방법에 의해 투여될 수 있다. 예를 들면, 국소적으로 근육 내, 피하 내 또는 다른 적절한 수단에 의해 투여될 수 있다.The pharmaceutical composition for the prevention and treatment of stress and panic disorder of the present invention is formulated as a preparation for parenteral administration, such as sterile aqueous solution, solution, non-aqueous solvent, suspension, emulsion, lyophilized preparation, suppository, injection Can be. Formulations for parenteral administration may include vegetable oils such as propylene glycol, polyethylene glycol, olive oil, and the like, injectable esters such as ethyl oleate, and the like. Formulations for parenteral administration can be administered by known methods. For example, it may be administered topically, intramuscularly, subcutaneously or by other suitable means.
바람직하게는 본 발명의 스트레스 및 공황장애의 예방 및 치료용 약학적 조성물은 비경구 투여를 위한 약침액으로 제조될 수 있다. 상기 약침액은 본 발명의 조성물을 증류하여 얻을 수 있으며, 다음과 같은 방법으로 제조될 수 있다. 상기 힐초근과 연자육을 세척하고 건조한 후 파쇄하여 분말화하고, 분말 형태의 힐초근과 연자육을 이의 건조중량의 2 내지 10 배의 증류수에 침지하여 80 내지 120 ℃의 온도에서 전탕한다. 전탕과정에서 발생한 증기를 냉각 순환 장치로 통과시켜 액체화하고 상기 액체의 상층액을 취한다. 상기 상층액의 pH 를 7 내지 7.5 로 조절하여 약침액을 얻을 수 있다. Preferably the pharmaceutical composition for the prevention and treatment of stress and panic disorder of the present invention may be prepared as a herbal acupuncture for parenteral administration. The immersion liquid may be obtained by distilling the composition of the present invention, and may be prepared by the following method. Washing and drying the heel grass root and lotus root meat, pulverized and powdered, and immersed in distilled water of 2 to 10 times the dry weight of the heel grass root and lotus root in the form of powder 80 Hot water at a temperature of from 120 ° C. to 120 ° C .; The steam generated during the pouring process is passed through a cooling circuit to liquefy and the supernatant of the liquid is taken. The pH of the supernatant can be adjusted to 7 to 7.5 to obtain a weak immersion liquid.
상기 약침액은 공지의 방법에 의해 투여될 수 있으며, 국소적으로 근육 내 또는 피하내 주사될 수 있다. 바람직하게는 상기 약침액은 혈위에 주사될 수 있으며, 보다 바람직하게는 견정혈과 관원혈에 주사될 수 있다. 상기 견정혈은 제 7 경추 하단(대추혈)과 견우혈(견관절의 삼각근 기시부 전방 함몰부)의 중간에 있는 경혈을 의미하며, 상기 관원혈은 치골결합 상연 중앙과 배꼽을 5 등분하여 배꼽에서 하방 3/5등분점을 의미한다. 상기 혈위에 약침액을 한혈당 0.2 내지 2.0 ㎖의 용량으로 투여할 수 있다. The acupuncture solution may be administered by a known method, and may be injected intramuscularly or subcutaneously. Preferably, the medicinal acupuncture solution may be injected into the blood level, and more preferably, may be injected into the acupoint blood and tube blood. The acupoint refers to acupuncture points in the middle of the lower part of the seventh cervical spine (the jujube blood) and the acupoint (the deltoid root anterior part of the shoulder joint). It means five points. The medicinal acupuncture solution may be administered at a dose of 0.2-2.0 ml per hemoglobin.
본 발명에 따른 약학적 조성물의 치료학적 또는 예방학적 유효량은 투여대상, 연령, 개인차 및 질병 상태에 따라 적절히 선택할 수 있다. 바람직하게는 본 발명의 약학적 조성물을 0.01 내지 1000mg/kg/day 범위로 투여할 수 있으며, 투여는 1일 1회, 또는 수회에 나누어 투여할 수 있다. The therapeutically or prophylactically effective amount of the pharmaceutical composition according to the present invention may be appropriately selected depending on the administration target, age, individual difference and disease state. Preferably the pharmaceutical composition of the present invention can be administered in the range of 0.01 to 1000 mg / kg / day, the administration may be administered once a day or divided into several times.
본 발명의 또한, 상기 본 발명의 약학적 조성물을 유효성분으로 포함하는 스트레스 및 공황장애 예방 및 개선용 건강기능식품을 제공한다. In addition, the present invention provides a health functional food for preventing and improving stress and panic disorder comprising the pharmaceutical composition of the present invention as an active ingredient.
상기 본 발명의 약학적 조성물은 각종 식품류, 유제품, 음료, 껌, 차, 비타민 복합제 및 엑기스등과 같은 건강 보조 식품류등에 첨가될 수 있고, 분말, 과립, 정제, 캡슐 또는 음료 형태일 수 있다. The pharmaceutical composition of the present invention may be added to various foods, dairy products, beverages, gums, teas, vitamin complexes and health supplements such as extracts, and the like, and may be in the form of powders, granules, tablets, capsules or beverages.
상기 약학적 조성물은 건강기능식품에 대하여 0.1 내지 10 중량부로 포함될 수 있다. 0.1 중량부 미만으로 포함되는 경우 스트레스 및 공황장애 예방 및 치료 효과가 미미할 수 있으며, 10 중량부를 초과하는 경우 건강기능식품에 맛이나 향에 영향을 미쳐 기호도가 저하될 수 있다. The pharmaceutical composition may be included in an amount of 0.1 to 10 parts by weight based on the health functional food. When included in less than 0.1 part by weight may be insignificant effect of the prevention and treatment of stress and panic disorder, when exceeding 10 parts by weight may affect the taste or aroma to the health functional food may decrease the preference.
상기 건강기능식품에는 상기 유효성분인 약학적 조성물외에 통상의 건강기능식품이나 음료등에 포함될 수 있는 성분이 제한없이 첨가될 수 있다. 구체적인 예로는 향미제 또는 천연탄수화물등이 포함될 수 있다. In addition to the pharmaceutical composition as the active ingredient, the health functional food may be added without limitation the ingredients that may be included in the general health functional food or beverages. Specific examples may include flavoring agents or natural carbohydrates.
이하, 실시예와 비교예를 통하여 본 발명을 상세히 설명한다. 이는 본 발명의 설명을 위한 것일 뿐, 이로 인해 본 발명의 범위가 제한되지 않는다. Hereinafter, the present invention will be described in detail through Examples and Comparative Examples. This is for the purpose of illustrating the invention only, and thus the scope of the invention is not limited.
<< 실시예Example 1> 스트레스 및 공황장애의 예방 및 치료용 1> Prevention and treatment of stress and panic disorder 환제의Pilled 제조 Produce
힐초근 및 연자육을 손질하여 건조한 뒤 파쇄하여 분말화하였다. 힐초근 분말 180 g, 연자육 분말 20 g 에 전분 10 g 및 증류수 50 ㎖를 가하여 혼합하고 직경 약 4 mm 정도의 환을 제조하였다. Heel root muscle and lotus root were trimmed, dried and crushed to powder. 10 g of starch and 50 ml of distilled water were added to 180 g of heel chorus root powder and 20 g of soft-fried meat powder, and the mixture was mixed to prepare a ring having a diameter of about 4 mm.
<< 실시예Example 2> 스트레스 및 공황장애의 예방 및 치료용 2> Prevention and treatment of stress and panic disorder 약침액의Medicinal 제조 Produce
냉각순환장치와 연결된 2 ℓ의 반응조에 힐초근 분말 180 g, 연자육 분말 20 g 을 넣고 3 차 증류수 1500 ㎖를 가한 뒤, 105 ℃에서 2 시간 동안 전탕하였다. 전탕과정중에서 발생한 증기는 냉각순환장치를 통과하여 액화되고 액화된 증기를 포집하여 이의 상층액을 분리하였다. 이렇게 수집된 상층액에 나트륨 인산염(Na3PO4)을 가하여 pH 를 7.25 내지 7.35 로 조절하여 약침액을 제조하였다. 180 g of hilcho root powder and 20 g of soft-fried meat powder were added to a 2 L reaction tank connected to a cooling circulation device, and 1500 ml of tertiary distilled water was added thereto, followed by pouring at 105 ° C. for 2 hours. The steam generated during the pouring process was passed through the cooling circulation system to collect the liquefied and liquefied steam to separate the supernatant thereof. Soak phosphate (Na 3 PO 4 ) was added to the collected supernatant to adjust the pH to 7.25 to 7.35 to prepare a weak solution.
<< 실시예Example 3> 스트레스 및 공황장애의 예방 및 치료용 3> Prevention and treatment of stress and panic disorder 약침액의Medicinal 제조 Produce
상기 실시예 2 에서 힐초근 분말 100 g 및 연자육 분말 100 g 을 사용한 것을 제외하고는 상기 실시예 2 와 동일하게 약침액을 제조하였다. A medicinal acupuncture solution was prepared in the same manner as in Example 2, except that 100 g of heel herb root powder and 100 g of soft gyros powder were used in Example 2.
<< 실시예Example 4> 4> 건강기능음료의Health functional drink 제조 Produce
힐초근 분말 500 mg, 연자육 분말 500 mg, 구연산 1000 mg, 올리고당, 100 g, 매실농축액 2 g, 타우린 1g 에 정제수를 가하여 전체를 900 ㎖로 만든 뒤 통상의 음료제조방법에 따라 상기의 성분을 혼합하여 스트레스 및 공황장애의 예방 및 개선용 건강기능음료를 제조하였다. 500 mg of heel chondroitin powder, 500 mg of lotus root powder, 1000 mg of citric acid, oligosaccharide, 100 g, 2 g of plum concentrate, 1 g of taurine and purified water were added to make 900 ml of the mixture, and the above ingredients were mixed according to the conventional beverage production method. To prepare a health functional drink for the prevention and improvement of stress and panic disorder.
<< 비교예Comparative example 1> 스트레스 및 공황장애의 예방 및 치료용 1> Prevention and treatment of stress and panic disorder 약침액의Medicinal 제조 Produce
냉각순환장치와 연결된 2 ℓ의 반응조에 힐초근 분말 200 g 을 넣고 3 차 증류수 1500 를 가한 뒤, 105 에서 2시간 동안 전탕하였다. 전탕과정중에서 발생한 증기는 냉각순환장치를 통과하여 액화되고 액화된 증기를 포집하여 이의 상층액을 분리하였다. 이렇게 수집된 상층액에 나트륨 인산염을 가하여 pH를 7.25 내지 7.35로 조절하여 약침액을 제조하였다.Into a 2 L reactor connected to the cooling cycle was added 200 g of Hilcho root powder, and the third distilled water 1500 was added, followed by hot water at 105 for 2 hours. The steam generated during the pouring process was passed through the cooling circulation system to collect the liquefied and liquefied steam to separate the supernatant thereof. Soak phosphate was added to the collected supernatant to adjust the pH to 7.25 to 7.35 to prepare a weak solution.
<< 실험예Experimental Example 1> 스트레스 유발 모델에서 장기 무게 변화 억제 효과 1> Inhibitory Effects of Organ Weight Changes on Stress-induced Models
스트레스가 유발되면 부신은 무게가 증가되며, 비장은 면역기능의 감퇴로 무게가 현저히 감소된다고 알려져 있다. 따라서, 본 실험에서는 부신 및 비장의 무게를 측정하여 스트레스에 대한 본 발명의 조성물의 효과를 측정하였다. When stress is induced, the adrenal gland increases in weight, and the spleen is known to significantly reduce its weight due to a decrease in immune function. Therefore, in this experiment, the weight of the adrenal and spleen was measured to determine the effect of the composition of the present invention on stress.
스트레스 유발에 대한 실험은 Selye법(Brekhaman, I.I:Llyoydia, Vol. 32, No. p 46~51, 1965) 을 사용하였다. 상기 실시예 2 내지 3 및 비교예 1 에서 제조한 약침액을 스트레스 유발전 2 시간전, 스트레스 유발후 6 시간 및 21 시간후에 사람의 견정혈에 해당하는 실험동물의 목의 시작점과 상지의 시작점의 중간점에 상기 실시예 및 비교예에서 제조한 약침액을 주사하였다. 실험동물을 모두 에테르로 마취시켜 장기를 적출하여 부신 및 비장의 무게를 측정하였으며 그 결과는 하기 표 1 과 같다. 하기 표 1 에서 정상군은 스트레스를 유발하지 않은 실험동물군을 의미하며, 양성 대조군은 스트레스 유발후 실시예 및 비교예의 약침액을 투여하지 않은 실험동물군을 의미한다. For experiments on stress induction, Selye method (Brekhaman, I.I: Llyoydia, Vol. 32, No. p 46 ~ 51, 1965) was used. The starting point of the start point of the neck and the start of the upper extremity of the experimental animal corresponding to the human acupoint blood 2 hours before the stress induced, 6 hours and 21 hours after the stress induced the medicinal acupuncture prepared in Examples 2 to 3 and Comparative Example 1 The medicinal needles prepared in Examples and Comparative Examples were injected into the midpoint. All the animals were anesthetized with ether to extract organs, and the weights of the adrenal and spleen were measured. The results are shown in Table 1 below. In the following Table 1, the normal group refers to the experimental animal group that did not cause stress, and the positive control group refers to the experimental animal group that did not administer the medicinal acupuncture solution of Examples and Comparative Examples after the stress was induced.
상기 표 1 에 의하면, 본 발명의 힐초근 및 연자육을 포함하는 약침액은 양성 대조군에 비해 비장의 무게가 감소하지 않았고, 부신의 무게도 크게 증가하지 않아 스트레스의 완화에 효과가 있음을 알 수 있고, 이에 따라 스트레스로 유발되는 질환에도 효과가 있음을 짐작할 수 있다. 또한, 본 발명의 약침액은 힐초근만 사용한 비교예의 약침액보다 스트레스 완화효과가 우수하였다. According to Table 1, the medicinal acupuncture solution containing the heel chokeuneun and yeonjak of the present invention did not reduce the weight of the spleen compared to the positive control, it can be seen that the weight of the adrenal gland does not significantly increase the effect of relieving stress Therefore, it can be expected that the effect is also effective in diseases caused by stress. In addition, the herbal medicinal solution of the present invention was superior to the stress relief effect of the herbal medicinal solution of the comparative example using only heel choke root.
<실험예 2> 불면증에 대한 효과 평가Experimental Example 2 Evaluation of Effect on Insomnia
스트레스로 인한 불면증에 시달리는 환자 50 명을 대상으로 상기 실시예 2 내지 3 및 비교예 1 의 약침액을 10 일간 1 일 1 회 견정혈과 관원혈에 주사한 후, 밤 10 시에 잠을 청하여 환자의 수면상태를 관찰하였다. 그 결과는 하기 표 2 와 같다.50 patients suffering from insomnia due to stress were injected with medicinal acupuncture of Examples 2 to 3 and Comparative Example 1 once a day for 10 days for septic and tuberculosis, and then went to sleep at 10 pm Sleep state was observed. The results are shown in Table 2 below.
잠이 든 환자수in 1 hour
Number of patients asleep
숙면한 환자수4 hours or more without breaking
Number of patients
숙면한 환자수6 hours or more without breaking
Number of patients
상기 표 2 에 의하면, 실시예의 약침액을 투여한 환자는 잠을 청한 후 1 시간이내에 90 % 이상의 환자가 잠들었으며, 이들의 대부분은 깨지 않고 4 시간 이상 숙면하였다. 또한, 힐초근만으로 제조된 비교예의 약침액도 불면증에 효과를 보이기는 했으나 실시예보다 효과가 적었다. 따라서, 본 발명의 조성물은 신경 안정 효과를 가져와 스트레스로 인한 불면증등에도 효과가 있는 것으로 나타났다. According to Table 2, the patient receiving the medicinal acupuncture of Example was asleep more than 90% of the patients within 1 hour after going to sleep, most of them were not awake and sleep more than 4 hours. In addition, the medicinal acupuncture solution of Comparative Example, which was prepared only by the heel herb, showed an effect on insomnia, but was less effective than the example. Therefore, the composition of the present invention has been shown to be effective in insomnia due to stress bringing a neurostable effect.
<실험예 3> 공황장애에 대한 평가Experimental Example 3 Evaluation of Panic Disorder
일반적으로 하기 표 3 의 13가지 증상중 4가지 이상에 해당되면 공항장애의 증후를 가진 것으로 판단할 수 있다.In general, if four or more of the 13 symptoms of Table 3, it can be determined that the symptoms of the airport disorder.
상기 공황장애의 13 가지 증상중 5 가지 이상을 가지고 있는 환자 15 명을 대상으로 상기 실시예 2 내지 3 및 비교예 1 의 조성물을 2개월간 1 일 1 회 투여한 후, 증상의 완화 정도를 환자와 상담하여 다음과 같은 기준으로 측정한 후 그 결과를 하기 표 4 에 나타내었다.After administering the compositions of Examples 2 to 3 and Comparative Example 1 once a day for 2 months to 15 patients having 5 or more of the 13 symptoms of panic disorder, the degree of relief of symptoms In consultation with the following criteria, the results are shown in Table 4 below.
완화된 환자수After one month the symptoms go away
Relaxed patients
완화된 환자수After 2 months the symptoms go away
Relaxed patients
상기 표 4 에 의하면, 실시예의 약침액을 투여한 환자의 경우 2 개월후에는 약 70% 이상의 환자가 불안이나 발작증상등 공황장애의 증상이 개선되거나 없어진것을 볼 수 있다. 또한, 비교예의 조성물에 비해 그 호전도가 빨랐다. According to Table 4, in the case of the administration of the medicinal acupuncture of the embodiment it can be seen that after about two months, about 70% or more patients improved or disappeared symptoms of panic disorder such as anxiety or seizure symptoms. Moreover, the improvement was quick compared with the composition of the comparative example.
상기에서 살펴본 바와 같이, 본 발명의 힐초근 및 연자육을 포함하는 스트레스 및 공황장애 예방 및 치료용 조성물은 스트레스를 완화하며 스트레스로 인한 불면증등의 질환도 개선하는 효과가 있을 뿐만 아니라 극도의 불안감, 발작등을 보이는 공황장애의 개선 효과가 우수하였다. 또한, 실험과정에서 환자로부터 부작용이나 거부감등이 보고되지 않아 본 발명의 약학적 조성물은 천연 유래의 물질을 포함하여 인체에 안전하고 장기간 사용하여도 인체에 무리가 없을 것으로 기대된다. As described above, the composition for the prevention and treatment of stress and panic disorder including the heel root and soft muscle of the present invention is effective in relieving stress and improving diseases such as insomnia due to stress as well as extreme anxiety and seizures. The improvement effect of panic disorder showing back was excellent. In addition, the side effects or rejection is not reported from the patient during the experiment process, the pharmaceutical composition of the present invention is expected to be safe to the human body, including a substance derived from nature, even if used for a long time.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020090077620A KR20110019977A (en) | 2009-08-21 | 2009-08-21 | Pharmaceutical composition for the prevention and treatment of stress and panic disorder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020090077620A KR20110019977A (en) | 2009-08-21 | 2009-08-21 | Pharmaceutical composition for the prevention and treatment of stress and panic disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20110019977A true KR20110019977A (en) | 2011-03-02 |
Family
ID=43929396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020090077620A Ceased KR20110019977A (en) | 2009-08-21 | 2009-08-21 | Pharmaceutical composition for the prevention and treatment of stress and panic disorder |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20110019977A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013129772A1 (en) * | 2012-02-27 | 2013-09-06 | 국립생물자원관 | Pharmaceutical composition comprising nelumbo nucifera seed extract as active ingredient for protecting brain nerve cells |
| KR20160004684A (en) | 2014-07-04 | 2016-01-13 | 원광대학교산학협력단 | A method for making gel of scolopendra subspinipes, the gel, a method for making medicine acupuncture liquid comprising the gel, and the medicine acupuncture liquid |
| KR20160042484A (en) | 2014-10-10 | 2016-04-20 | 원광대학교산학협력단 | A method of making injection liquid comprising scolopendra subspinipes for neurodegenerative disease, and the injection liquid made by the method |
-
2009
- 2009-08-21 KR KR1020090077620A patent/KR20110019977A/en not_active Ceased
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013129772A1 (en) * | 2012-02-27 | 2013-09-06 | 국립생물자원관 | Pharmaceutical composition comprising nelumbo nucifera seed extract as active ingredient for protecting brain nerve cells |
| KR20160004684A (en) | 2014-07-04 | 2016-01-13 | 원광대학교산학협력단 | A method for making gel of scolopendra subspinipes, the gel, a method for making medicine acupuncture liquid comprising the gel, and the medicine acupuncture liquid |
| KR20160042484A (en) | 2014-10-10 | 2016-04-20 | 원광대학교산학협력단 | A method of making injection liquid comprising scolopendra subspinipes for neurodegenerative disease, and the injection liquid made by the method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6064156B2 (en) | Deep body temperature raising agent | |
| KR101609535B1 (en) | Anti-arthritis and cartilage protective herbal preparations containing reduced cucurbitacin B | |
| CN103598460A (en) | Forage for preventing infectious bronchitis of chicken | |
| CN104147385B (en) | A kind of formula of Chinese medicine for lowering blood pressure preparation and preparation method | |
| KR101189108B1 (en) | A composition containing dendropanax morbifera extract for improving sexual function | |
| KR101690175B1 (en) | Pharmaceutical composition for preventing or treating insomnia comprising Angelica tenuissima extract | |
| KR101826737B1 (en) | A composition containing herbs extract, and manufacturing method of the same | |
| KR101012415B1 (en) | Arthritis prevention or treatment composition and method for producing same | |
| KR20150057333A (en) | Composition comprising extract of korean fir for preventing and improving obesity | |
| CN107519310B (en) | Traditional Chinese medicine composition and preparation process for improving energy and inhibiting tumor cell growth | |
| CN110973625A (en) | Liver-protecting and sobering-up composition based on fructus cannabis and preparation method and application thereof | |
| KR20110019977A (en) | Pharmaceutical composition for the prevention and treatment of stress and panic disorder | |
| KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
| KR101999742B1 (en) | Composition comprising ethanol extract of Aster scaber for preventon or treatment of neuropathic pain | |
| KR101821925B1 (en) | A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis | |
| KR20200061285A (en) | Food Composition for blood circulation and for Preventing blood vessel disease Comprising Extract of Galangal | |
| WO2008069604A1 (en) | Composition comprising the mixed herbal extract of aralia cordata thunb. and cimicifuga heracleifolia kom. for preventing and treating inflammatory disease and pain disease | |
| KR20160081205A (en) | Composition comprising extract of hydrangea serrata for preventing and improving obesity | |
| KR101738206B1 (en) | A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis | |
| KR101600745B1 (en) | A pharmaceutical composition comprising the complex extract of herb medicine | |
| CN110063977B (en) | Radix codonopsis and sea buckthorn composite electuary and application thereof | |
| KR101421347B1 (en) | A method for preparing the essential oil fraction showing potent anti-obesity and inhibiting activity on fatty liver from Angelica gigas Nakai and the composition comprising the same the prevention or treatment of obesity and fatty liver | |
| KR20120134770A (en) | Composition for inhibiting obesity containing shiso leaf extract | |
| KR100850503B1 (en) | Composition for improving erectile dysfunction and erection maintenance containing the extract of crude drug complex | |
| KR20150110949A (en) | A composition for preventing, treating and improving of voiding disorder comprising herbal extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20090821 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20110322 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20111122 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20110322 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |